Psychedelics Enter Public Markets, Optimi CEO Points to Supply Bottleneck

The Trump administration’s executive order to ease psychedelic research restrictions has pushed the sector back into the policy and capital markets conversation. The order includes a $50 million federal research investment and directs federal agencies to accelerate work around psychedelic therapies, including ibogaine, for mental health treatment. FDA Commissioner Marty Makary also said three psychedelic programs would be added to the agency’s National Priority Voucher pilot program, which is designed to shorten review timelines for certain priority treatments.

For investors, the timing matters. The global psychedelic drugs market was valued at $6.33 billion in 2025 and is projected to reach $13.67 billion by 2030, according to sectoral publications, reflecting a 16.7% compound annual growth rate.

Optimi Looks to Supply the Regulated Market

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) has applied to list on Nasdaq under the ticker OPTH in connection with a proposed U.S. underwritten public offering. The company describes itself as a commercial-stage pharmaceutical manufacturer focused on GMP-grade psychedelic drug products, including MDMA and botanical psilocybin.

Unlike companies built primarily around drug discovery, Optimi is positioning itself around pharmaceutical supply. The company says its products are currently prescribed in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. It also operates two 10,000-square-foot facilities in British Columbia for validated MDMA and botanical psilocybin products.

Dane Stevens: Supply Readiness Comes Before Demand

In written responses to IgniteIt, Optimi CEO Dane Stevens said the executive order could accelerate activity across agencies, universities, and capital markets, but that the real bottleneck is manufacturing.

“The supply side bottleneck shifts to qualified manufacturing the moment policy moves,” Stevens said. “Very few facilities globally can deliver pharmaceutical-grade, DEA-scheduled, clinically validated material with the documentation regulators require. Optimi is one of them.”

“The days following the order showed how real the federal posture is. The FDA awarded three Commissioner’s National Priority Vouchers to psychedelic programs that had previously received Breakthrough Therapy designation. The CNPV mechanism is designed to compress FDA review from roughly ten to twelve months down to one to two.”

Stevens highlighted current demand is concentrated in Australia, where psilocybin and MDMA have been prescribable since July 2023 for treatment-resistant depression and PTSD under the TGA’s Authorised Prescriber scheme.

For investors, he framed Optimi differently from a pre-revenue clinical development story.

“We’re a manufacturer. That’s a deliberate choice,” Stevens said, adding that Optimi generates revenue from “real prescriptions and trial supply rather than from a pre-revenue clinical thesis.”

“The model we’re building toward looks more like the ketamine market. Ketamine has shown what broad patient access can look like when you have differentiated supply chains, insurance pathways, and competitive pricing for the people who actually need the medicine. That combination is what makes a therapy real at scale, and it’s the model we want to see psychedelics follow,” Stevens continued.

Why Infrastructure Could Define the Next Phase

Stevens compared the future of psychedelics more closely to ketamine than cannabis, arguing that broader adoption will depend on supply chains, insurance pathways, and pricing.

The operational standard, he said, is consistency.

“The bottleneck is the qualified manufacturer count. You cannot run a Phase 3 trial on inconsistent material, and you cannot commercialize a therapy on it either,” Stevens noted. “Every dose has to be identical, traceable, and produced under conditions regulators have inspected and approved.”

“As the category scales, programs needing pharmaceutical-grade material will flow through a small number of qualified suppliers. That’s where we’ve positioned the company. Therapeutic protocols and clinical sponsors will compete with each other for patients and indications. The supply layer underneath them is far less crowded and far harder to replicate,” Stevens added.

A Market Moving From Research to Execution

The U.S. policy shift does not legalize or reclassify psychedelics, and the FDA and DEA remain central to oversight. Still, the combination of federal research momentum, public market activity, and real-world prescription programs abroad suggests the sector is entering a more practical phase.

“Optimi sits on the supply side. Drug developers carry binary clinical risk. A qualified manufacturer with commercial revenue and GMP infrastructure has a different profile, and we think it’s a more durable position as the category matures, Stevens noted. “It also matters that the MDMA and psilocybin Optimi manufactures could potentially be prescribed for whichever indication a country allows. We’re not tied to a single therapeutic outcome. As more jurisdictions approve more uses, the same supply infrastructure scales across them, which reduces the indication risk most companies in this space carry.”

As Stevens put it, “Supply readiness has to precede demand.”

For companies and investors watching psychedelic medicine, that may be the real story: not just whether therapies advance, but whether the infrastructure exists to deliver them at scale.